Signal transduction of β2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts

Xuening (Neal) Chen, Kalisha D. O'Neill, Toshimitsu Niwa, Sharon Moe

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. β2 microglobulin (β2m) amyloidosis is a destructive articular disease affecting dialysis patients. We have demonstrated that β2m increases the expression of vascular cell adhesion molecule (VCAM-1) and cyclooxygenase-2 (COX-2) in human osteoarthritic synovial fibroblasts (SFLs). Methods. To determine the cell signaling pathways, SFLs were incubated with β2m in the presence or absence of various inhibitors for 24 hours. Intracellular calcium ([Ca2+]i) was measured by fluorometric techniques and vascular cell adhesion molecule-1 (VCAM-1) and cyclooxygenase-2 (COX-2) expression was determined by immunohistochemistry and Western blotting. Results. β2 increased [Ca2+]i levels in a dose dependent manner (P < 0.05) in SFLs. BAPTA-AM, a [Ca2+]i chelator, completely inhibited β2m-induced expression of VCAM-1 and COX-2. U73122 [phospholipase C (PLC) inhibitor] or 2-APB [specific inhibitor of inositol 1,4,5-trisphosphate (IP3)-induced [Ca2+]i release] completely blocked the β2m-induced increase in [Ca2+]i and the up-regulation of VCAM-1 and COX-2. However, pretreatment with staurosporin, a protein kinase C inhibitor, had no effect. Disruption of the actin cytoskeleton by treatment with cytochalasin D or latrunculin A blocked β2m up-regulation of VCAM-1 and COX-2. Finally, cells treated with phosphatidylinositol-3 kinase (PI-3 kinase) inhibitors wortmannin or LY294002 also failed to express VCAM-1 and COX-2. Conclusions. These results demonstrate that IP3-mediated [Ca2+]i release, PI-3 kinase, and actin cytoskeleton reorganizatio are involved in β2m-induced expression of VCAM-1 and COX-2 in human SFLs. Understanding the potential pathways by which β2m exerts its inflammatory-like effects may lead to the development of future therapies.

Original languageEnglish
Pages (from-to)414-424
Number of pages11
JournalKidney International
Volume61
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Vascular Cell Adhesion Molecule-1
Cyclooxygenase 2
Signal Transduction
Fibroblasts
Phosphatidylinositol 3-Kinase
Actin Cytoskeleton
Up-Regulation
Cytochalasin D
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Inositol 1,4,5-Trisphosphate
Protein C Inhibitor
Type C Phospholipases
Amyloidosis
Protein Kinase Inhibitors
Chelating Agents
Protein Kinase C
Dialysis
Joints
Western Blotting
Immunohistochemistry

Keywords

  • Actin cytoskeleton
  • Articular disease
  • Cell signaling
  • Gene expression
  • Intracellular calcium
  • Phosphatidylinositol-3 kinase

ASJC Scopus subject areas

  • Nephrology

Cite this

Signal transduction of β2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts. / Chen, Xuening (Neal); O'Neill, Kalisha D.; Niwa, Toshimitsu; Moe, Sharon.

In: Kidney International, Vol. 61, No. 2, 2002, p. 414-424.

Research output: Contribution to journalArticle

@article{703439388ee341c2a830c347d1c310d1,
title = "Signal transduction of β2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts",
abstract = "Background. β2 microglobulin (β2m) amyloidosis is a destructive articular disease affecting dialysis patients. We have demonstrated that β2m increases the expression of vascular cell adhesion molecule (VCAM-1) and cyclooxygenase-2 (COX-2) in human osteoarthritic synovial fibroblasts (SFLs). Methods. To determine the cell signaling pathways, SFLs were incubated with β2m in the presence or absence of various inhibitors for 24 hours. Intracellular calcium ([Ca2+]i) was measured by fluorometric techniques and vascular cell adhesion molecule-1 (VCAM-1) and cyclooxygenase-2 (COX-2) expression was determined by immunohistochemistry and Western blotting. Results. β2 increased [Ca2+]i levels in a dose dependent manner (P < 0.05) in SFLs. BAPTA-AM, a [Ca2+]i chelator, completely inhibited β2m-induced expression of VCAM-1 and COX-2. U73122 [phospholipase C (PLC) inhibitor] or 2-APB [specific inhibitor of inositol 1,4,5-trisphosphate (IP3)-induced [Ca2+]i release] completely blocked the β2m-induced increase in [Ca2+]i and the up-regulation of VCAM-1 and COX-2. However, pretreatment with staurosporin, a protein kinase C inhibitor, had no effect. Disruption of the actin cytoskeleton by treatment with cytochalasin D or latrunculin A blocked β2m up-regulation of VCAM-1 and COX-2. Finally, cells treated with phosphatidylinositol-3 kinase (PI-3 kinase) inhibitors wortmannin or LY294002 also failed to express VCAM-1 and COX-2. Conclusions. These results demonstrate that IP3-mediated [Ca2+]i release, PI-3 kinase, and actin cytoskeleton reorganizatio are involved in β2m-induced expression of VCAM-1 and COX-2 in human SFLs. Understanding the potential pathways by which β2m exerts its inflammatory-like effects may lead to the development of future therapies.",
keywords = "Actin cytoskeleton, Articular disease, Cell signaling, Gene expression, Intracellular calcium, Phosphatidylinositol-3 kinase",
author = "Chen, {Xuening (Neal)} and O'Neill, {Kalisha D.} and Toshimitsu Niwa and Sharon Moe",
year = "2002",
doi = "10.1046/j.1523-1755.2002.00136.x",
language = "English",
volume = "61",
pages = "414--424",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Signal transduction of β2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts

AU - Chen, Xuening (Neal)

AU - O'Neill, Kalisha D.

AU - Niwa, Toshimitsu

AU - Moe, Sharon

PY - 2002

Y1 - 2002

N2 - Background. β2 microglobulin (β2m) amyloidosis is a destructive articular disease affecting dialysis patients. We have demonstrated that β2m increases the expression of vascular cell adhesion molecule (VCAM-1) and cyclooxygenase-2 (COX-2) in human osteoarthritic synovial fibroblasts (SFLs). Methods. To determine the cell signaling pathways, SFLs were incubated with β2m in the presence or absence of various inhibitors for 24 hours. Intracellular calcium ([Ca2+]i) was measured by fluorometric techniques and vascular cell adhesion molecule-1 (VCAM-1) and cyclooxygenase-2 (COX-2) expression was determined by immunohistochemistry and Western blotting. Results. β2 increased [Ca2+]i levels in a dose dependent manner (P < 0.05) in SFLs. BAPTA-AM, a [Ca2+]i chelator, completely inhibited β2m-induced expression of VCAM-1 and COX-2. U73122 [phospholipase C (PLC) inhibitor] or 2-APB [specific inhibitor of inositol 1,4,5-trisphosphate (IP3)-induced [Ca2+]i release] completely blocked the β2m-induced increase in [Ca2+]i and the up-regulation of VCAM-1 and COX-2. However, pretreatment with staurosporin, a protein kinase C inhibitor, had no effect. Disruption of the actin cytoskeleton by treatment with cytochalasin D or latrunculin A blocked β2m up-regulation of VCAM-1 and COX-2. Finally, cells treated with phosphatidylinositol-3 kinase (PI-3 kinase) inhibitors wortmannin or LY294002 also failed to express VCAM-1 and COX-2. Conclusions. These results demonstrate that IP3-mediated [Ca2+]i release, PI-3 kinase, and actin cytoskeleton reorganizatio are involved in β2m-induced expression of VCAM-1 and COX-2 in human SFLs. Understanding the potential pathways by which β2m exerts its inflammatory-like effects may lead to the development of future therapies.

AB - Background. β2 microglobulin (β2m) amyloidosis is a destructive articular disease affecting dialysis patients. We have demonstrated that β2m increases the expression of vascular cell adhesion molecule (VCAM-1) and cyclooxygenase-2 (COX-2) in human osteoarthritic synovial fibroblasts (SFLs). Methods. To determine the cell signaling pathways, SFLs were incubated with β2m in the presence or absence of various inhibitors for 24 hours. Intracellular calcium ([Ca2+]i) was measured by fluorometric techniques and vascular cell adhesion molecule-1 (VCAM-1) and cyclooxygenase-2 (COX-2) expression was determined by immunohistochemistry and Western blotting. Results. β2 increased [Ca2+]i levels in a dose dependent manner (P < 0.05) in SFLs. BAPTA-AM, a [Ca2+]i chelator, completely inhibited β2m-induced expression of VCAM-1 and COX-2. U73122 [phospholipase C (PLC) inhibitor] or 2-APB [specific inhibitor of inositol 1,4,5-trisphosphate (IP3)-induced [Ca2+]i release] completely blocked the β2m-induced increase in [Ca2+]i and the up-regulation of VCAM-1 and COX-2. However, pretreatment with staurosporin, a protein kinase C inhibitor, had no effect. Disruption of the actin cytoskeleton by treatment with cytochalasin D or latrunculin A blocked β2m up-regulation of VCAM-1 and COX-2. Finally, cells treated with phosphatidylinositol-3 kinase (PI-3 kinase) inhibitors wortmannin or LY294002 also failed to express VCAM-1 and COX-2. Conclusions. These results demonstrate that IP3-mediated [Ca2+]i release, PI-3 kinase, and actin cytoskeleton reorganizatio are involved in β2m-induced expression of VCAM-1 and COX-2 in human SFLs. Understanding the potential pathways by which β2m exerts its inflammatory-like effects may lead to the development of future therapies.

KW - Actin cytoskeleton

KW - Articular disease

KW - Cell signaling

KW - Gene expression

KW - Intracellular calcium

KW - Phosphatidylinositol-3 kinase

UR - http://www.scopus.com/inward/record.url?scp=0036007339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036007339&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2002.00136.x

DO - 10.1046/j.1523-1755.2002.00136.x

M3 - Article

C2 - 11849381

AN - SCOPUS:0036007339

VL - 61

SP - 414

EP - 424

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -